Regulation of insulin synthesis and secretion and pancreatic beta-cell dysfunction in diabetes

Current Diabetes Reviews

Volumn 9, Issue 1, 2013, Pages 25-53

  Fu, Zhuo ^a   Gilbert, Elizabeth R ^a   Liu, Dongmin ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

And insulin synthesis; Diabetes; Glucose; Hormones; Insulin secretion; cell

Indexed keywords

AMINO ACID; C PEPTIDE; CYCLIC AMP; CYCLIN DEPENDENT KINASE 5; ESTROGEN; FATTY ACID; GLUCAGON LIKE PEPTIDE 1; GLUCOKINASE; GLUCOSE; GLUCOSE TRANSPORTER 2; GROWTH HORMONE; HEXOKINASE; INITIATION FACTOR 2ALPHA; INSULIN; LEPTIN; MELATONIN; NEUROGENIC DIFFERENTIATION FACTOR; PHOSPHOPROTEIN PHOSPHATASE 1; PREPROINSULIN; PROINSULIN; PROPROTEIN CONVERTASE 2; PROTEIN C JUN; REACTIVE OXYGEN METABOLITE; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR 7; TRANSCRIPTION FACTOR 7 LIKE 2; TRANSCRIPTION FACTOR PAX6; TRANSCRIPTION FACTOR PDX 1; ZINC TRANSPORTER;

5' UNTRANSLATED REGION; ACHAETE SCUTE COMPLEX; APOPTOSIS; ARTICLE; AUTOIMMUNITY; BASIC LEUCINE ZIPPER MOTIF; BINDING AFFINITY; CALCIUM CELL LEVEL; CELL FUNCTION; CELL REGENERATION; CELL SURVIVAL; CITRIC ACID CYCLE; CONSENSUS SEQUENCE; CRYSTAL STRUCTURE; DIABETES MELLITUS; DIABETIC PATIENT; DNA BINDING; DNA FLANKING REGION; DNA PROTEIN COMPLEX; ENDOPLASMIC RETICULUM STRESS; ENERGY METABOLISM; ENHANCER REGION; EXOCYTOSIS; FATTY ACID METABOLISM; GENE CONTROL; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE SENSOR; GLYCOLYSIS; HUMAN; HYPERINSULINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN SYNTHESIS; INTRACELLULAR SIGNALING; LIPOTOXICITY; LONG TERM EXPOSURE; MITOCHONDRION; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; SECRETORY GRANULE; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; UNFOLDED PROTEIN RESPONSE;

EID: 84875966088     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339913804143225     Document Type: Article

References (500)

1. Pittman I, L Philipson, D Steiner. Insulin biosynthesis, secretion, structure, and structure-activity relationships. http://diabetesmanager.pbworks.com/w/page/17680216/Insulin%20Biosynthesis,%20Secretion,%20Structure,%20and%20Structure-Activity%20Relationships 2004.
2. De Meyts P. Insulin and its receptor: structure, function and evolution. Bioessays 2004; 26(12): 1351-1362.
3. De Meyts P, J Whittaker. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 2002; 1(10): 769-783.
4. Abel JJ. Crystalline insulin. Proc. Natl. Acad. Sci. 1926; 12: 132-136.
5. Blundell TL, JF Cutfield, EJ Dodson, GG Dodson, DC Hodgkin, DA Mercola. The crystal structure of rhombohedral 2 zinc insulin. Cold Spring Harb Symp Quant Biol 1972; 36: 233-241.
6. Blundell TL, JF Cutfield, SM Cutfield, et al. Three-dimensional atomic structure of insulin and its relationship to activity. Diabetes 1972; 21(2 Suppl): 492-505.
7. Blundell TL, JF Cutfield, SM Cutfield, et al. Atomic positions in rhombohedral 2-zinc insulin crystals. Nature 1971; 231(5304): 506-511.
8. Baker EN, TL Blundell, JF Cutfield, et al. The structure of 2 Zn pig insulin crystals at 1.5 A resolution. Philos. Trans. R. Soc. London. 1988; B319: 369-456.
9. Smith GD, WA Pangborn, RH Blessing. The structure of T6 human insulin at 1.0 A resolution. Acta Crystallogr D Biol Crystallogr 2003; 59(Pt 3): 474-482.
10. Dodson GG, JL Whittingham. Insulin: sequence, structure and function - a story of surprises. In: Insulin and related proteins -structure to function and pharmacology. Springer: New York 2002: 29-39.
11. Pullen RA, DG Lindsay, SP Wood, et al. S Gammeltoft. Receptorbinding region of insulin. Nature 1976; 259(5542): 369-373.
12. Hua QX, SE Shoelson, M Kochoyan, MA Weiss. Receptor binding redefined by a structural switch in a mutant human insulin. Nature 1991; 354(6350): 238-241.
13. Ludvigsen S, HB Olsen, NC Kaarsholm. A structural switch in a mutant insulin exposes key residues for receptor binding. J Mol Biol 1998; 279(1): 1-7.
14. Kwok SC, DF Steiner, AH Rubenstein, HS Tager. Identification of a point mutation in the human insulin gene giving rise to a structurally abnormal insulin (insulin Chicago). Diabetes 1983; 32(9): 872-875.
15. Shoelson S, M Haneda, P Blix, et al. Three mutant insulins in man. Nature 1983; 302(5908): 540-543.
16. Shoelson S, M Fickova, M Haneda, et al. Identification of a mutant human insulin predicted to contain a serine-for-phenylalanine substitution. Proc Natl Acad Sci U S A 1983; 80(24): 7390-7394.
17. Kobayashi M, S Ohgaku, M Iwasaki, H Maegawa, Y Shigeta, K Inouye. Characterization of [LeuB-24]- and [LeuB-25]-insulin analogues. Receptor binding and biological activity. Biochem J 1982; 206(3): 597-603.
18. Kobayashi M, S Ohgaku, M Iwasaki, H Maegawa, Y Shigeta, K Inouye. Supernormal insulin: [D-PheB24]-insulin with increased affinity for insulin receptors. Biochem Biophys Res Commun 1982; 107(1): 329-336.
19. Nanjo K, T Sanke, M Miyano, et al. Diabetes due to secretion of a structurally abnormal insulin (insulin Wakayama). Clinical and functional characteristics of [LeuA3 insulin. J Clin Invest 1986; 77(2): 514-519.
20. Wollmer A, B Rannefeld, BR Johansen, KR Hejnaes, P Balschmidt, FB Hansen. Phenol-promoted structural transformation of insulin in solution. Biol Chem Hoppe Seyler 1987; 368(8): 903-911.
21. Ogawa H, GT Burke, JD Chanley, PG Katsoyannis. Effect of Nmethylation of selected peptide bonds on the biological activity of insulin. [2-N-methylisoleucine-A]insulin and [3-N-methylvaline-A]insulin. Int J Pept Protein Res 1987; 30(4): 460-473.
22. Schwartz G, PG Katsoyannis. Synthesis of des(tetrapeptide B(1-4)) and des(pentapeptide B(1-5)) human insulins. Two biologically active analogues. Biochemistry 1978; 17(21): 4550-4556.
23. Nakagawa SH, HS Tager. Implications of invariant residue LeuB6 in insulin-receptor interactions. J Biol Chem 1991; 266(18): 11502-11509.
24. Chan SJ, S Seino, PA Gruppuso, R Schwartz, DF Steiner. A mutation in the B chain coding region is associated with impaired proinsulin conversion in a family with hyperproinsulinemia. Proc Natl Acad Sci U S A 1987; 84(8): 2194-2197.
25. Gruppuso PA, P Gorden, CR Kahn, M Cornblath, WP Zeller, R Schwartz. Familial hyperproinsulinemia due to a proposed defect in conversion of proinsulin to insulin. N Engl J Med 1984; 311(10): 629-634.
26. Schwartz GP, GT Burke, PG Katsoyannis. A superactive insulin: [B10-aspartic acid]insulin(human). Proc Natl Acad Sci U S A 1987; 84(18): 6408-6411.
27. Egea PF, RM Stroud, P Walter. Targeting proteins to membranes: structure of the signal recognition particle. Curr Opin Struct Biol 2005; 15(2): 213-220.
28. Chan SJ, P Keim, DF Steiner. Cell-free synthesis of rat preproinsulins: characterization and partial amino acid sequence determination. Proc Natl Acad Sci U S A 1976; 73(6): 1964-1968.
29. Lomedico PT, SJ Chan, DF Steiner, GF Saunders. Immunological and chemical characterization of bovine preproinsulin. J Biol Chem 1977; 252(22): 7971-798.
30. Patzelt C, AD Labrecque, JR Duguid, RJ Carroll, PS Keim, RL Heinrikson, DF Steiner. Detection and kinetic behavior of preproinsulin in pancreatic islets. Proc Natl Acad Sci U S A 1978; 75(3): 1260-1264.
31. Huang XF, P Arvan. Intracellular transport of proinsulin in pancreatic beta-cells. Structural maturation probed by disulfide accessibility. J Biol Chem 1995; 270(35): 20417-20423.
32. Munro S, HR Pelham. A C-terminal signal prevents secretion of luminal ER proteins. Cell 1987; 48(5): 899-907.
33. Steiner DF KW, Clark JL, Oyer PE, Rubenstein A. The biosynthesis of insulin. In: Steiner DF, Freinkel N (eds) Handbook of physiology-Section 7 Endocrinology I. Williams & Wilkins, Baltimore. 1972: PP 175-198.
34. Nishi M, T Sanke, S Nagamatsu, GI Bell, DF Steiner. Islet amyloid polypeptide. A new beta cell secretory product related to islet amyloid deposits. J Biol Chem 1990; 265(8): 4173-4176.
35. Poitout V, D Hagman, R Stein, I Artner, RP Robertson, JS Harmon. Regulation of the insulin gene by glucose and fatty acids. J Nutr 2006; 136(4): 873-876.
36. Giddings SJ, J Chirgwin, MA Permutt. Effects of glucose on proinsulin messenger RNA in rats in vivo. Diabetes 1982; 31(7): 624-629.
37. Welsh M, DA Nielsen, AJ MacKrell, DF Steiner. Control of insulin gene expression in pancreatic beta-cells and in an insulin-producing cell line, RIN-5F cells. II. Regulation of insulin mRNA stability. J Biol Chem 1985; 260(25): 13590-13594.
38. Knopp RH, RO Bergelin, PW Wahl, CE Walden. Relationships of infant birth size to maternal lipoproteins, apoproteins, fuels, hormones, clinical chemistries, and body weight at 36 weeks gestation. Diabetes 1985; 34 Suppl 2: 71-77.
39. Knoch KP, R Meisterfeld, S Kersting, et al. cAMP-dependent phosphorylation of PTB1 promotes the expression of insulin secretory granule proteins in beta cells. Cell Metab 2006; 3(2): 123-134.
40. Soares MB, E Schon, A Henderson, et al. RNA-mediated gene duplication: the rat preproinsulin I gene is a functional retroposon. Mol Cell Biol 1985; 5(8): 2090-2103.
41. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985; 315(6015): 115-122.
42. Bucchini D, MA Ripoche, MG Stinnakre, et al. Pancreatic expression of human insulin gene in transgenic mice. Proc Natl Acad Sci U S A 1986; 83(8): 2511-2515.
43. Crowe DT, MJ Tsai. Mutagenesis of the rat insulin II 5'-flanking region defines sequences important for expression in HIT cells. Mol Cell Biol 1989; 9(4): 1784-1789.
44. Edlund T, MD Walker, PJ Barr, WJ Rutter. Cell-specific expression of the rat insulin gene: evidence for role of two distinct 5' flanking elements. Science 1985; 230(4728): 912-916.
45. Melloul D, Y Ben-Neriah, E Cerasi. Glucose modulates the binding of an islet-specific factor to a conserved sequence within the rat I and the human insulin promoters. Proc Natl Acad Sci U S A 1993; 90(9): 3865-3869.
46. Sharma A, R Stein. Glucose-induced transcription of the insulin gene is mediated by factors required for beta-cell-type-specific expression. Mol Cell Biol 1994; 14(2): 871-879.
47. Whelan J, D Poon, PA Weil, R Stein. Pancreatic beta-cell-typespecific expression of the rat insulin II gene is controlled by positive and negative cellular transcriptional elements. Mol Cell Biol 1989; 9(8): 3253-3259.
48. Dean PM. Ultrastructural morphometry of the pancreatic -cell. Diabetologia 1973; 9(2): 115-119.
49. Howell SL. The mechanism of insulin secretion. Diabetologia 1984; 26(5): 319-327.
50. Hay CW, K Docherty. Comparative analysis of insulin gene promoters: implications for diabetes research. Diabetes 2006; 55(12): 3201-3213.
51. Steiner DF, SJ Chan, JM Welsh, SC Kwok. Structure and evolution of the insulin gene. Annu Rev Genet 1985; 19: 463-484.
52. German M, S Ashcroft, K Docherty, et al. The insulin gene promoter. A simplified nomenclature. Diabetes 1995; 44(8): 1002-1004.
53. Gehring WJ, M Affolter, T Burglin. Homeodomain proteins. Annu Rev Biochem 1994; 63: 487-526.
54. Trainor PA, R Krumlauf. Hox genes, neural crest cells and branchial arch patterning. Curr Opin Cell Biol 2001; 13(6): 698-705.
55. Ohlsson H, K Karlsson, T Edlund. IPF1, a homeodomaincontaining transactivator of the insulin gene. Embo J 1993; 12(11): 4251-4259.
56. Leonard J, B Peers, T Johnson, K Ferreri, S Lee, MR Montminy. Characterization of somatostatin transactivating factor-1, a novel homeobox factor that stimulates somatostatin expression in pancreatic islet cells. Mol Endocrinol 1993; 7(10): 1275-1283.
57. Miller CP, RE McGehee, Jr., JF Habener. IDX-1: a new homeodomain transcription factor expressed in rat pancreatic islets and duodenum that transactivates the somatostatin gene. Embo J 1994; 13(5): 1145-1156.
58. German MS, J Wang, RB Chadwick, WJ Rutter. Synergistic activation of the insulin gene by a LIM-homeo domain protein and a basic helix-loop-helix protein: building a functional insulin minienhancer complex. Genes Dev 1992; 6(11): 2165-2176.
59. Karlsson O, S Thor, T Norberg, H Ohlsson, T Edlund. Insulin gene enhancer binding protein Isl-1 is a member of a novel class of proteins containing both a homeo- and a Cys-His domain. Nature 1990; 344(6269): 879-882.
60. Peshavaria M, L Gamer, E Henderson, G Teitelman, CV Wright, R Stein. XIHbox 8, an endoderm-specific Xenopus homeodomain protein, is closely related to a mammalian insulin gene transcription factor. Mol Endocrinol 1994; 8(6): 806-816.
61. Petersen HV, P Serup, J Leonard, BK Michelsen, OD Madsen. Transcriptional regulation of the human insulin gene is dependent on the homeodomain protein STF1/IPF1 acting through the CT boxes. Proc Natl Acad Sci U S A 1994; 91(22): 10465-10469.
62. Peers B, J Leonard, S Sharma, G Teitelman, MR Montminy. Insulin expression in pancreatic islet cells relies on cooperative interactions between the helix loop helix factor E47 and the homeobox factor STF-1. Mol Endocrinol 1994; 8(12): 1798-1806.
63. Guz Y, MR Montminy, R Stein, et al. Expression of murine STF-1, a putative insulin gene transcription factor, in beta cells of pancreas, duodenal epithelium and pancreatic exocrine and endocrine progenitors during ontogeny. Development 1995; 121(1): 11-18.
64. Wu KL, M Gannon, M Peshavaria, et al. Hepatocyte nuclear factor 3beta is involved in pancreatic beta-cell-specific transcription of the pdx-1 gene. Mol Cell Biol 1997; 17(10): 6002-6013.
65. Chawengsaksophak K, R James, VE Hammond, F Kontgen, F Beck. Homeosis and intestinal tumours in Cdx2 mutant mice. Nature 1997; 386(6620): 84-87.
66. Thor S, J Ericson, T Brannstrom, T Edlund. The homeodomain LIM protein Isl-1 is expressed in subsets of neurons and endocrine cells in the adult rat. Neuron 1991; 7(6): 881-889.
67. Leonard J, P Serup, G Gonzalez, T Edlund, M Montminy. The LIM family transcription factor Isl-1 requires cAMP response element binding protein to promote somatostatin expression in pancreatic islet cells. Proc Natl Acad Sci U S A 1992; 89(14): 6247-6251.
68. Wang M, DJ Drucker. The LIM domain homeobox gene isl-1 is a positive regulator of islet cell-specific proglucagon gene transcription. J Biol Chem 1995; 270(21): 12646-12652.
69. Wang M, DJ Drucker. Activation of amylin gene transcription by LIM domain homeobox gene isl-1. Mol Endocrinol 1996; 10(3): 243-251.
70. Ahlgren U, SL Pfaff, TM Jessell, T Edlund, H Edlund. Independent requirement for ISL1 in formation of pancreatic mesenchyme and islet cells. Nature 1997; 385(6613): 257-260.
71. Shieh SY, MJ Tsai. Cell-specific and ubiquitous factors are responsible for the enhancer activity of the rat insulin II gene. J Biol Chem 1991; 266(25): 16708-16714.
72. Zhao L, MA Cissell, E Henderson, R Colbran, R Stein. The RIPE3b1 activator of the insulin gene is composed of a protein(s) of approximately 43 kDa, whose DNA binding activity is inhibited by protein phosphatase treatment. J Biol Chem 2000; 275(14): 10532-10537.
73. Shieh SY, CM Stellrecht, MJ Tsai. Molecular characterization of the rat insulin enhancer-binding complex 3b2. Cloning of a binding factor with putative helicase motifs. J Biol Chem 1995; 270(37): 21503-21508.
74. Kataoka K, SI Han, S Shioda, M Hirai, M Nishizawa, H Handa. MafA is a glucose-regulated and pancreatic beta-cell-specific transcriptional activator for the insulin gene. J Biol Chem 2002; 277(51): 49903-49910.
75. Matsuoka TA, L Zhao, I Artner, et al. Members of the large Maf transcription family regulate insulin gene transcription in islet beta cells. Mol Cell Biol 2003; 23(17): 6049-6062.
76. Olbrot M, J Rud, LG Moss, A Sharma. Identification of beta-cellspecific insulin gene transcription factor RIPE3b1 as mammalian MafA. Proc Natl Acad Sci U S A 2002; 99(10): 6737-6742.
77. Matsuoka TA, I Artner, E Henderson, A Means, M Sander, R Stein. The MafA transcription factor appears to be responsible for tissue-specific expression of insulin. Proc Natl Acad Sci U S A 2004; 101(9): 2930-2933.
78. Zhao L, M Guo, TA Matsuoka, et al. The islet beta cell-enriched MafA activator is a key regulator of insulin gene transcription. J Biol Chem 2005; 280(12): 11887-11894.
79. Hagman DK, LB Hays, SD Parazzoli, V Poitout. Palmitate inhibits insulin gene expression by altering PDX-1 nuclear localization and reducing MafA expression in isolated rat islets of Langerhans. J Biol Chem 2005; 280(37): 32413-32418.
80. Harmon JS, R Stein, RP Robertson. Oxidative stress-mediated, post-translational loss of MafA protein as a contributing mechanism to loss of insulin gene expression in glucotoxic beta cells. J Biol Chem 2005; 280(12): 11107-11113.
81. Zhang C, T Moriguchi, M Kajihara, et al. MafA is a key regulator of glucose-stimulated insulin secretion. Mol Cell Biol 2005; 25(12): 4969-4976.
82. Knepel W, M Vallejo, JA Chafitz, JF Habener. The pancreatic islet-specific glucagon G3 transcription factors recognize control elements in the rat somatostatin and insulin-I genes. Mol Endocrinol 1991; 5(10): 1457-1466.
83. Sander M, A Neubuser, J Kalamaras, HC Ee, GR Martin, MS German. Genetic analysis reveals that PAX6 is required for normal transcription of pancreatic hormone genes and islet development. Genes Dev 1997; 11(13): 1662-1673.
84. Sosa-Pineda B, K Chowdhury, M Torres, G Oliver, P Gruss. The Pax4 gene is essential for differentiation of insulin-producing beta cells in the mammalian pancreas. Nature 1997; 386(6623): 399-402.
85. Sosa-Pineda B. The gene Pax4 is an essential regulator of pancreatic beta-cell development. Mol Cells 2004; 18(3): 289-94.
86. German MS, LG Moss, J Wang, WJ Rutter. The insulin and islet amyloid polypeptide genes contain similar cell-specific promoter elements that bind identical beta-cell nuclear complexes. Mol Cell Biol 1992; 12(4): 1777-1788.
87. Whelan J, SR Cordle, E Henderson, PA Weil, R Stein. Identification of a pancreatic beta-cell insulin gene transcription factor that binds to and appears to activate cell-type-specific expression: its possible relationship to other cellular factors that bind to a common insulin gene sequence. Mol Cell Biol 1990; 10(4): 1564-1572.
88. Buskin JN, SD Hauschka. Identification of a myocyte nuclear factor that binds to the muscle-specific enhancer of the mouse muscle creatine kinase gene. Mol Cell Biol 1989; 9(6): 2627-2640.
89. Ephrussi A, GM Church, S Tonegawa, W Gilbert. B lineage--specific interactions of an immunoglobulin enhancer with cellular factors in vivo. Science 1985; 227(4683): 134-140.
90. Davis RL, H Weintraub, AB Lassar. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 1987; 51(6): 987-1000.
91. Braun T, G Buschhausen-Denker, E Bober, E Tannich, HH Arnold. A novel human muscle factor related to but distinct from MyoD1 induces myogenic conversion in 10T1/2 fibroblasts. Embo J 1989; 8(3): 701-709.
92. Brennan TJ, EN Olson. Myogenin resides in the nucleus and acquires high affinity for a conserved enhancer element on heterodimerization. Genes Dev 1990; 4(4): 582-595.
93. Cabrera CV, A Martinez-Arias, M Bate. The expression of three members of the achaete-scute gene complex correlates with neuroblast segregation in Drosophila. Cell 1987; 50(3): 425-433.
94. Naya FJ, CM Stellrecht, MJ Tsai. Tissue-specific regulation of the insulin gene by a novel basic helix-loop-helix transcription factor. Genes Dev 1995; 9(8): 1009-1019.
95. Lee JE, SM Hollenberg, L Snider, DL Turner, N Lipnick, H Weintraub. Conversion of Xenopus ectoderm into neurons by NeuroD, a basic helix-loop-helix protein. Science 1995; 268(5212): 836-844.
96. Cordle SR, E Henderson, H Masuoka, PA Weil, R Stein. Pancreatic beta-cell-type-specific transcription of the insulin gene is mediated by basic helix-loop-helix DNA-binding proteins. Mol Cell Biol 1991; 11(3): 1734-1738.
97. German MS, MA Blanar, C Nelson, LG Moss, WJ Rutter. Two related helix-loop-helix proteins participate in separate cell-specific complexes that bind the insulin enhancer. Mol Endocrinol 1991; 5(2): 292-299.
98. Peyton M, LG Moss, MJ Tsai. Two distinct class A helix-loophelix transcription factors, E2A and BETA1, form separate DNA binding complexes on the insulin gene E box. J Biol Chem 1994; 269(41): 25936-25941.
99. Naya FJ, HP Huang, Y Qiu, et al. Diabetes, defective pancreatic morphogenesis, and abnormal enteroendocrine differentiation in BETA2/neuroD-deficient mice. Genes Dev 1997; 11(18): 2323-2334.
100. Huang HP, K Chu, E Nemoz-Gaillard, D Elberg, MJ Tsai. Neogenesis of beta-cells in adult BETA2/NeuroD-deficient mice. Mol Endocrinol 2002; 16(3): 541-551.
101. Sander M, SC Griffen, J Huang, MS German. A novel glucoseresponsive element in the human insulin gene functions uniquely in primary cultured islets. Proc Natl Acad Sci U S A 1998; 95(20): 11572-11577.
102. Boam DS, AR Clark, K Docherty. Positive and negative regulation of the human insulin gene by multiple trans-acting factors. J Biol Chem 1990; 265(14): 8285-8296.
103. Le Lay J, R Stein. Involvement of PDX-1 in activation of human insulin gene transcription. J Endocrinol 2006; 188(2): 287-294.
104. Pino MF, DZ Ye, KD Linning, et al. Elevated glucose attenuates human insulin gene promoter activity in INS-1 pancreatic beta-cells via reduced nuclear factor binding to the A5/core and Z element. Mol Endocrinol 2005; 19(5): 1343-1360.
105. Inagaki N, T Maekawa, T Sudo, S Ishii, Y Seino, H Imura. C-Jun represses the human insulin promoter activity that depends on multiple cAMP response elements. Proc Natl Acad Sci U S A 1992; 89(3): 1045-1049.
106. Hay CW, EM Sinclair, G Bermano, E Durward, M Tadayyon, K Docherty. Glucagon-like peptide-1 stimulates human insulin promoter activity in part through cAMP-responsive elements that lie upstream and downstream of the transcription start site. J Endocrinol 2005; 186(2): 353-365.
107. Foulkes NS, P Sassone-Corsi. Transcription factors coupled to the cAMP-signalling pathway. Biochim Biophys Acta 1996; 1288(3): F101-F121.
108. Metallo SJ, DN Paolella, A Schepartz. The role of a basic amino acid cluster in target site selection and non-specific binding of bZIP peptides to DNA. Nucleic Acids Res 1997; 25(15): 2967-2972.
109. Emens LA, DW Landers, LG Moss. Hepatocyte nuclear factor 1 alpha is expressed in a hamster insulinoma line and transactivates the rat insulin I gene. Proc Natl Acad Sci U S A 1992; 89(16): 7300-7304.
110. Peng SY, WP Wang, J Meng, et al. ISL1 physically interacts with BETA2 to promote insulin gene transcriptional synergy in non-beta cells. Biochim Biophys Acta 2005; 1731(3): 154-159.
111. Ohneda K, RG Mirmira, J Wang, JD Johnson, MS German. The homeodomain of PDX-1 mediates multiple protein-protein interactions in the formation of a transcriptional activation complex on the insulin promoter. Mol Cell Biol 2000; 20(3): 900-911.
112. Suckale J, M Solimena. Pancreas islets in metabolic signaling-- focus on the beta-cell. Front Biosci 2008; 13: 7156-7171.
113. Vander Mierde D, D Scheuner, R Quintens, et al. Glucose activates a protein phosphatase-1-mediated signaling pathway to enhance overall translation in pancreatic beta-cells. Endocrinology 2007; 148(2): 609-617.
114. Elouil H, M Bensellam, Y Guiot, et al. Acute nutrient regulation of the unfolded protein response and integrated stress response in cultured rat pancreatic islets. Diabetologia 2007; 50(7): 1442-1452.
115. Wicksteed B, Y Uchizono, C Alarcon, JF McCuaig, A Shalev, CJ Rhodes. A cis-element in the 5' untranslated region of the preproinsulin mRNA (ppIGE) is required for glucose regulation of proinsulin translation. Cell Metab 2007; 5(3): 221-227.
116. Shi Y, KM Vattem, R Sood, J An, J Liang, L Stramm, RC Wek. Identification and characterization of pancreatic eukaryotic initiation factor 2 alpha-subunit kinase, PEK, involved in translational control. Mol Cell Biol 1998; 18(12): 7499-7509.
117. Harding HP, I Novoa, Y Zhang, et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell 2000; 6(5): 1099-1108.
118. Harding HP, H Zeng, Y Zhang, et al. Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival. Mol Cell 2001; 7(6): 1153-1163.
119. Scheuner D, B Song, E McEwen, et al. Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Mol Cell 2001; 7(6): 1165-1176.
120. Delepine M, M Nicolino, T Barrett, M Golamaully, GM Lathrop, C Julier. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet 2000; 25(4): 406-409.
121. Zhang W, D Feng, Y Li, K Iida, B McGrath, DR Cavener. PERK EIF2AK3 control of pancreatic beta cell differentiation and proliferation is required for postnatal glucose homeostasis. Cell Metab 2006; 4(6): 491-497.
122. Fonseca SG, M Fukuma, KL Lipson, et al. WFS1 is a novel component of the unfolded protein response and maintains homeostasis of the endoplasmic reticulum in pancreatic beta-cells. J Biol Chem 2005; 280(47): 39609-39615.
123. Pirot P, N Naamane, F Libert, et al. Global profiling of genes modified by endoplasmic reticulum stress in pancreatic beta cells reveals the early degradation of insulin mRNAs. Diabetologia 2007; 50(5): 1006-1014.
124. Ortsater H, A Sjoholm. A busy cell--endoplasmic reticulum stress in the pancreatic beta-cell. Mol Cell Endocrinol 2007; 277(1-2): 1-5.
125. Varadi A, T Tsuboi, LI Johnson-Cadwell, VJ Allan, GA Rutter. Kinesin I and cytoplasmic dynein orchestrate glucose-stimulated insulin-containing vesicle movements in clonal MIN6 beta-cells. Biochem Biophys Res Commun 2003; 311(2): 272-282.
126. Ort T, E Maksimova, R Dirkx, et al. The receptor tyrosine phosphatase-like protein ICA512 binds the PDZ domains of beta2- syntrophin and nNOS in pancreatic beta-cells. Eur J Cell Biol 2000; 79(9): 621-630.
127. Mziaut H, M Trajkovski, S Kersting, et al. Synergy of glucose and growth hormone signalling in islet cells through ICA512 and STAT5. Nat Cell Biol 2006; 8(5): 435-445.
128. toh N, H Okamoto. Translational control of proinsulin synthesis by glucose. Nature 1980; 283(5742): 100-102.
129. Permutt MA, DM Kipnis. Insulin biosynthesis. I. On the mechanism of glucose stimulation. J Biol Chem 1972; 247(4): 1194-1199.
130. Izquierdo JM, N Majos, S Bonnal, et al. Regulation of Fas alternative splicing by antagonistic effects of TIA-1 and PTB on exon definition. Mol Cell 2005; 19(4): 475-484.
131. Spellman R, CW Smith. Novel modes of splicing repression by PTB. Trends Biochem Sci 2006; 31(2): 73-76.
132. Wollerton MC, C Gooding, EJ Wagner, MA Garcia-Blanco, CW Smith. Autoregulation of polypyrimidine tract binding protein by alternative splicing leading to nonsense-mediated decay. Mol Cell 2004; 13(1): 91-100.
133. Schmitz O, J Rungby, L Edge, CB Juhl. On high-frequency insulin oscillations. Ageing Res Rev 2008; 7(4): 301-305.
134. Chang TW, AL Goldberg. The metabolic fates of amino acids and the formation of glutamine in skeletal muscle. J Biol Chem 1978; 253(10): 3685-3693.
135. Maechler P, CB Wollheim. Mitochondrial glutamate acts as a messenger in glucose-induced insulin exocytosis. Nature 1999; 402(6762): 685-689.
136. Eto K, Y Tsubamoto, Y Terauchi, et al. Role of NADH shuttle system in glucose-induced activation of mitochondrial metabolism and insulin secretion. Science 1999; 283(5404): 981-985.
137. Bender K, P Newsholme, L Brennan, P Maechler. The importance of redox shuttles to pancreatic beta-cell energy metabolism and function. Biochem Soc Trans 2006; 34(Pt 5): 811-814.
138. Sener A, WJ Malaisse. L-leucine and a nonmetabolized analogue activate pancreatic islet glutamate dehydrogenase. Nature 1980; 288(5787): 187-189.
139. Dixon G, J Nolan, N McClenaghan, PR Flatt, P Newsholme. A comparative study of amino acid consumption by rat islet cells and the clonal beta-cell line BRIN-BD11 - the functional significance of L-alanine. J Endocrinol 2003; 179(3): 447-454.
140. Tang-Christensen M, PJ Larsen, J Thulesen, JR Nielsen, N Vrang. [Glucagon-like peptide 2, a neurotransmitter with a newly discovered role in the regulation of food ingestion]. Ugeskr Laeger 2001; 163(3): 287-291.
141. MacDonald PE, W El-Kholy, MJ Riedel, AM Salapatek, PE Light, MB Wheeler. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002; 51 Suppl 3: S434-S442.
142. MacDonald PE, AM Salapatek, MB Wheeler. Glucagon-like peptide-1 receptor activation antagonizes voltage-dependent repolarizing K(+) currents in beta-cells: a possible glucosedependent insulinotropic mechanism. Diabetes 2002; 51 Suppl 3: S443-A447.
143. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51(1): 7-18.
144. Nolan CJ, JL Leahy, V Delghingaro-Augusto, J Moibi, K Soni, ML Peyot, M Fortier, C Guay, J Lamontagne, A Barbeau, E Przybytkowski, E Joly, P Masiello, S Wang, GA Mitchell, M Prentki. Beta cell compensation for insulin resistance in Zucker fatty rats: increased lipolysis and fatty acid signalling. Diabetologia 2006; 49(9): 2120-2130.
145. Prentki M, E Joly, W El-Assaad, R Roduit. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes 2002; 51 Suppl 3: S405-S413.
146. Crespin SR, WB Greenough, 3rd, D Steinberg. Stimulation of insulin secretion by infusion of free fatty acids. J Clin Invest 1969; 48(10): 1934-1943.
147. Roduit R, C Nolan, C Alarcon, et al. A role for the malonyl- CoA/long-chain acyl-CoA pathway of lipid signaling in the regulation of insulin secretion in response to both fuel and nonfuel stimuli. Diabetes 2004; 53(4): 1007-1019.
148. Stein DT, V Esser, BE Stevenson, et al. Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. J Clin Invest 1996; 97(12): 2728-2735.
149. Briscoe CP, M Tadayyon, JL Andrews, et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 2003; 278(13): 11303-11311.
150. Itoh Y, Y Kawamata, M Harada, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003; 422(6928): 173-176.
151. Prentki M. New insights into pancreatic beta-cell metabolic signaling in insulin secretion. Eur J Endocrinol 1996; 134(3): 272-286.
152. Chapman ER, J Blasi, S An, et al. Fatty acylation of synaptotagmin in PC12 cells and synaptosomes. Biochem Biophys Res Commun 1996; 225(1): 326-332.
153. Gonzalo S, ME Linder. SNAP-25 palmitoylation and plasma membrane targeting require a functional secretory pathway. Mol Biol Cell 1998; 9(3): 585-597.
154. Prentki M, FM Matschinsky. Ca2+, cAMP, and phospholipidderived messengers in coupling mechanisms of insulin secretion. Physiol Rev 1987; 67(4): 1185-1248.
155. Rhee JS, A Betz, S Pyott, et al. Beta phorbol ester- and diacylglycerol-induced augmentation of transmitter release is mediated by Munc13s and not by PKCs. Cell 2002; 108(1): 121-133.
156. Kashyap S, R Belfort, A Gastaldelli, et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003; 52(10): 2461-2474.
157. Salehi A, BG Fan, M Ekelund, G Nordin, I Lundquist. TPN-evoked dysfunction of islet lysosomal activity mediates impairment of glucose-stimulated insulin release. Am J Physiol Endocrinol Metab 2001; 281(1): E171-E179.
158. Schulla V, E Renstrom, R Feil, et al. Impaired insulin secretion and glucose tolerance in beta cell-selective Ca(v)1.2 Ca2+ channel null mice. Embo J 2003; 22(15): 3844-3854.
159. Bratanova-Tochkova TK, H Cheng, S Daniel, et al. Triggering and augmentation mechanisms, granule pools, and biphasic insulin secretion. Diabetes 2002; 51 Suppl 1: S83-S90.
160. Straub SG, GW Sharp. Hypothesis: one rate-limiting step controls the magnitude of both phases of glucose-stimulated insulin secretion. Am J Physiol Cell Physiol 2004; 287(3): C565-C571.
161. Olofsson CS, SO Gopel, S Barg, et al. Fast insulin secretion reflects exocytosis of docked granules in mouse pancreatic B-cells. Pflugers Arch 2002; 444(1-2): 43-51.
162. Daniel S, M Noda, SG Straub, GW Sharp. Identification of the docked granule pool responsible for the first phase of glucosestimulated insulin secretion. Diabetes 1999; 48(9): 1686-1690.
163. Kang L, Z He, P Xu, et al. Munc13-1 is required for the sustained release of insulin from pancreatic beta cells. Cell Metab 2006; 3(6): 463-468.
164. Kwan EP, L Xie, L Sheu, et al. Munc13-1 deficiency reduces insulin secretion and causes abnormal glucose tolerance. Diabetes 2006; 55(5): 1421-1429.
165. Gerst JE. SNARE regulators: matchmakers and matchbreakers. Biochim Biophys Acta 2003; 1641(2-3): 99-110.
166. Hatsuzawa K, T Lang, D Fasshauer, D Bruns, R Jahn. The RSNARE motif of tomosyn forms SNARE core complexes with syntaxin 1 and SNAP-25 and down-regulates exocytosis. J Biol Chem 2003; 278(33): 31159-31166.
167. Cheviet S, P Bezzi, R Ivarsson, et al. Tomosyn-1 is involved in a post-docking event required for pancreatic beta-cell exocytosis. J Cell Sci 2006; 119(Pt 14): 2912-2920.
168. Yizhar O, U Matti, R Melamed, et al. Tomosyn inhibits priming of large dense-core vesicles in a calcium-dependent manner. Proc Natl Acad Sci U S A 2004; 101(8): 2578-2583.
169. Gauthier BR, CB Wollheim. Synaptotagmins bind calcium to release insulin. Am J Physiol Endocrinol Metab 2008; 295(6): E1279-E1286.
170. Eliasson L, X Ma, E Renstrom, et al. SUR1 regulates PKAindependent cAMP-induced granule priming in mouse pancreatic B-cells. J Gen Physiol 2003; 121(3): 181-197.
171. Fujimoto K, T Shibasaki, N Yokoi, et al. Piccolo, a Ca2+ sensor in pancreatic beta-cells. Involvement of cAMP-GEFII.Rim2.Piccolo complex in cAMP-dependent exocytosis. J Biol Chem 2002; 277(52): 50497-50502.
172. Catterall WA. Structure and function of neuronal Ca2+ channels and their role in neurotransmitter release. Cell Calcium 1998; 24(5-6): 307-323.
173. Catterall WA. Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol 2000; 16: 521-555.
174. Dolphin AC. L-type calcium channel modulation. Adv Second Messenger Phosphoprotein Res 1999; 33: 153-177.
175. Reid CA, JM Bekkers, JD Clements. Presynaptic Ca2+ channels: a functional patchwork. Trends Neurosci 2003; 26(12): 683-687.
176. Heady TN, JC Gomora, TL Macdonald, E Perez-Reyes. Molecular pharmacology of T-type Ca2+ channels. Jpn J Pharmacol 2001; 85(4): 339-350.
177. Perez-Reyes E. Molecular physiology of low-voltage-activated ttype calcium channels. Physiol Rev 2003; 83(1): 117-161.
178. Triggle DJ. The physiological and pharmacological significance of cardiovascular T-type, voltage-gated calcium channels. Am J Hypertens 1998; 11(4 Pt 3): 80S-87S.
179. Jing X, DQ Li, CS Olofsson, et al. CaV2.3 calcium channels control second-phase insulin release. J Clin Invest 2005; 115(1): 146-154.
180. Vajna R, U Klockner, A Pereverzev, et al. Functional coupling between 'R-type' Ca2+ channels and insulin secretion in the insulinoma cell line INS-1. Eur J Biochem 2001; 268(4): 1066-1075.
181. Vignali S, V Leiss, R Karl, F Hofmann, A Welling. Characterization of voltage-dependent sodium and calcium channels in mouse pancreatic A- and B-cells. J Physiol 2006; 572(Pt 3): 691-706.
182. Rorsman P, G Trube. Calcium and delayed potassium currents in mouse pancreatic beta-cells under voltage-clamp conditions. J Physiol 1986; 374: 531-550.
183. Gromada J, M Hoy, E Renstrom, et al. CaM kinase II-dependent mobilization of secretory granules underlies acetylcholine-induced stimulation of exocytosis in mouse pancreatic B-cells. J Physiol 1999; 518 (Pt 3): 745-759.
184. Henquin JC. The interplay between cyclic AMP and ions in the stimulus-secretion coupling in pancreatic B-cells. Arch Int Physiol Biochim 1985; 93(1): 37-48.
185. Malaisse WJ, F Malaisse-Lagae. The role of cyclic AMP in insulin release. Experientia 1984; 40(10): 1068-1074.
186. Sutherland EW, GA Robison. The role of cyclic AMP in the control of carbohydrate metabolism. Diabetes 1969; 18(12): 797-819.
187. Charles MA, R Fanska, FG Schmid, PH Forsham, GM Grodsky. Adenosine 3',5'-monophosphate in pancreatic islets: glucoseinduced insulin release. Science 1973; 179(73): 569-571.
188. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 2001; 142(2): 521-527.
189. Meier JJ, MA Nauck, WE Schmidt, B Gallwitz. Gastric inhibitory polypeptide: the neglected incretin revisited. Regul Pept 2002; 107(1-3): 1-13.
190. Jones PM, SJ Persaud. Protein kinases, protein phosphorylation, and the regulation of insulin secretion from pancreatic beta-cells. Endocr Rev 1998; 19(4): 429-461.
191. Renstrom E, L Eliasson, P Rorsman. Protein kinase A-dependent and -independent stimulation of exocytosis by cAMP in mouse pancreatic B-cells. J Physiol 1997; 502 (Pt 1): 105-118.
192. Ozaki N, T Shibasaki, Y Kashima, et al. S Seino. cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol 2000; 2(11): 805-811.
193. de Rooij J, FJ Zwartkruis, MH Verheijen, RH Cool, SM Nijman, A Wittinghofer, JL Bos. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998; 396(6710): 474-477.
194. Kawasaki H, GM Springett, N Mochizuki, et al. A family of cAMP-binding proteins that directly activate Rap1. Science 1998; 282(5397): 2275-2279.
195. Kang G, OG Chepurny, B Malester, et al. cAMP sensor Epac as a determinant of ATP-sensitive potassium channel activity in human pancreatic beta cells and rat INS-1 cells. J Physiol 2006; 573(Pt 3): 595-609.
196. Fujimoto K, T Shibasaki, N Yokoi, et al. Piccolo, a Ca2+ sensor in pancreatic beta-cells. Involvement of cAMP-GEFII.Rim2. Piccolo complex in cAMP-dependent exocytosis. J Biol Chem 2002; 277(52): 50497-50502.
197. Wang Y, M Okamoto, F Schmitz, K Hofmann, TC Sudhof. Rim is a putative Rab3 effector in regulating synaptic-vesicle fusion. Nature 1997; 388(6642): 593-598.
198. Gundelfinger ED, MM Kessels, B Qualmann. Temporal and spatial coordination of exocytosis and endocytosis. Nat Rev Mol Cell Biol 2003; 4(2): 127-139.
199. de Rooij J, H Rehmann, M van Triest, RH Cool, A Wittinghofer, JL Bos. Mechanism of regulation of the Epac family of cAMPdependent RapGEFs. J Biol Chem 2000; 275(27): 20829-20836.
200. Kuno T, H Shuntoh, M Sakaue, K et al. Site-directed mutagenesis of the cAMP-binding sites of the recombinant type I regulatory subunit of cAMP-dependent protein kinase. Biochem Biophys Res Commun 1988; 153(3): 1244-1250.
201. Ringheim GE, SS Taylor. Effects of cAMP-binding site mutations on intradomain cross-communication in the regulatory subunit of cAMP-dependent protein kinase I. J Biol Chem 1990; 265(32): 19472-1948.
202. Stark JM, M Jasin. Extensive loss of heterozygosity is suppressed during homologous repair of chromosomal breaks. Mol Cell Biol 2003; 23(2): 733-743.
203. Kashima Y, T Miki, T Shibasaki, et al. Critical role of cAMPGEFII--Rim2 complex in incretin-potentiated insulin secretion. J Biol Chem 2001; 276(49): 46046-46053.
204. Nakazaki M, A Crane, M Hu, et al. cAMP-activated protein kinaseindependent potentiation of insulin secretion by cAMP is impaired in SUR1 null islets. Diabetes 2002; 51(12): 3440-3449.
205. Shiota C, O Larsson, KD Shelton, et al. Sulfonylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose. J Biol Chem 2002; 277(40): 37176-37183.
206. Schmidt M, S Evellin, PA Weernink, et al. A new phospholipase-C-calcium signalling pathway mediated by cyclic AMP and a Rap GTPase. Nat Cell Biol 2001; 3(11): 1020-1024.
207. Shibasaki T, Y Sunaga, S Seino. Integration of ATP, cAMP, and Ca2+ signals in insulin granule exocytosis. Diabetes 2004; 53 Suppl 3: S59-S62.
208. Barg S, P Huang, L Eliasson, et al. Priming of insulin granules for exocytosis by granular Cl(-) uptake and acidification. J Cell Sci 2001; 114(Pt 11): 2145-2154.
209. Kang G, OG Chepurny, GG Holz. cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic beta-cells. J Physiol 2001; 536(Pt 2): 375-385.
210. Kang G, JW Joseph, OG Chepurny, et al. Epac-selective cAMP analog 8-pCPT-2'-O-Me-cAMP as a stimulus for Ca2+-induced Ca2+ release and exocytosis in pancreatic beta-cells. J Biol Chem 2003; 278(10): 8279-8285.
211. Bode HP, B Moormann, R Dabew, B Goke. Glucagon-like peptide 1 elevates cytosolic calcium in pancreatic beta-cells independently of protein kinase A. Endocrinology 1999; 140(9): 3919-3927.
212. Kang G, OG Chepurny, MJ Rindler, et al. A cAMP and Ca2+ coincidence detector in support of Ca2+-induced Ca2+ release in mouse pancreatic beta cells. J Physiol 2005; 566(Pt 1): 173-188.
213. Holz GG, G Kang, M Harbeck, MW Roe, OG Chepurny. Cell physiology of cAMP sensor Epac. J Physiol 2006; 577(Pt 1): 5-15.
214. Nadal A, AB Ropero, O Laribi, M Maillet, E Fuentes, B Soria. Nongenomic actions of estrogens and xenoestrogens by binding at a plasma membrane receptor unrelated to estrogen receptor alpha and estrogen receptor beta. Proc Natl Acad Sci U S A 2000; 97(21): 11603-11608.
215. Sutter-Dub MT. Rapid non-genomic and genomic responses to progestogens, estrogens, and glucocorticoids in the endocrine pancreatic B cell, the adipocyte and other cell types. Steroids 2002; 67(2): 77-93.
216. Nadal A, JM Rovira, O Laribi, et al. Rapid insulinotropic effect of 17beta-estradiol via a plasma membrane receptor. FASEB J 1998; 12(13): 1341-1348.
217. Stevenson JC, D Crook, IF Godsland, P Collins, MI Whitehead. Hormone replacement therapy and the cardiovascular system. Nonlipid effects. Drugs 1994; 47 Suppl 2: 35-41.
218. Brussaard HE, JA Gevers Leuven, M Frolich, C Kluft, HM Krans. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia 1997; 40(7): 843-849.
219. Ropero AB, B Soria, A Nadal. A nonclassical estrogen membrane receptor triggers rapid differential actions in the endocrine pancreas. Mol Endocrinol 2002; 16(3): 497-505.
220. Hawkins MB, JW Thornton, D Crews, JK Skipper, A Dotte, P Thomas. Identification of a third distinct estrogen receptor and reclassification of estrogen receptors in teleosts. Proc Natl Acad Sci U S A 2000; 97(20): 10751-10756.
221. Ropero AB, E Fuentes, JM Rovira, C Ripoll, B Soria, A Nadal. Non-genomic actions of 17beta-oestradiol in mouse pancreatic beta-cells are mediated by a cGMP-dependent protein kinase. J Physiol 1999; 521 Pt 2: 397-407.
222. Sheng M, G McFadden, ME Greenberg. Membrane depolarization and calcium induce c-fos transcription via phosphorylation of transcription factor CREB. Neuron 1990; 4(4): 571-582.
223. Cartin L, KM Lounsbury, MT Nelson. Coupling of Ca(2+) to CREB activation and gene expression in intact cerebral arteries from mouse: roles of ryanodine receptors and voltage-dependent Ca(2+) channels. Circ Res 2000; 86(7): 760-767.
224. Shaywitz AJ, ME Greenberg. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 1999; 68: 821-861.
225. Mayr B, M Montminy. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2001; 2(8): 599-609.
226. Arendt J. Melatonin and the mammalian pineal gland. Chapman and Hall: London. 1994.
227. Peschke E, E Muhlbauer, U Musshoff, VJ Csernus, E Chankiewitz, D Peschke. Receptor (MT(1)) mediated influence of melatonin on cAMP concentration and insulin secretion of rat insulinoma cells INS-1. J Pineal Res 2002; 33(2): 63-71.
228. Kemp DM, M Ubeda, JF Habener. Identification and functional characterization of melatonin Mel 1a receptors in pancreatic beta cells: potential role in incretin-mediated cell function by sensitization of cAMP signaling. Mol Cell Endocrinol 2002; 191(2): 157-166.
229. Ramracheya RD, DS Muller, PE Squires, et al. Function and expression of melatonin receptors on human pancreatic islets. J Pineal Res 2008; 44(3): 273-279.
230. Peschke E. Melatonin, endocrine pancreas and diabetes. J Pineal Res 2008; 44(1): 26-40.
231. Bailey CJ, TW Atkins, AJ Matty. Melatonin inhibition of insulin secretion in the rat and mouse. Horm Res 1974; 5(1): 21-28.
232. Frankel BJ, MJ Strandberg. Insulin release from isolated mouse islets in vitro: no effect of physiological levels of melatonin or arginine vasotocin. J Pineal Res 1991; 11(3-4): 145-148.
233. Peschke E, AG Bach, E Muhlbauer. Parallel signaling pathways of melatonin in the pancreatic beta-cell. J Pineal Res 2006; 40(2): 184-191.
234. Lyssenko V, CL Nagorny, MR Erdos, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 2009; 41(1): 82-88.
235. Peschke E, D Peschke, T Hammer, V Csernus. Influence of melatonin and serotonin on glucose-stimulated insulin release from perifused rat pancreatic islets in vitro. J Pineal Res 1997; 23(3): 156-163.
236. Picinato MC, EP Haber, J Cipolla-Neto, et al. Melatonin inhibits insulin secretion and decreases PKA levels without interfering with glucose metabolism in rat pancreatic islets. J Pineal Res 2002; 33(3): 156-160.
237. Nishida S, T Segawa, I Murai, S Nakagawa. Long-term melatonin administration reduces hyperinsulinemia and improves the altered fatty-acid compositions in type 2 diabetic rats via the restoration of Delta-5 desaturase activity. J Pineal Res 2002; 32(1): 26-33.
238. von Gall C, JH Stehle, DR Weaver. Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res 2002; 309(1): 151-162.
239. Petit L, I Lacroix, P de Coppet, AD Strosberg, R Jockers. Differential signaling of human Mel1a and Mel1b melatonin receptors through the cyclic guanosine 3'-5'-monophosphate pathway. Biochem Pharmacol 1999; 58(4): 633-639.
240. Bach AG, S Wolgast, E Muhlbauer, E Peschke. Melatonin stimulates inositol-1,4,5-trisphosphate and Ca2+ release from INS1 insulinoma cells. J Pineal Res 2005; 39(3): 316-323.
241. Godson C, SM Reppert. The Mel1a melatonin receptor is coupled to parallel signal transduction pathways. Endocrinology 1997; 138(1): 397-404.
242. Orskov C. Glucagon-like peptide-1, a new hormone of the enteroinsular axis. Diabetologia 1992; 35(8): 701-711.
243. Flint A, A Raben, A Astrup, JJ Holst. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101(3): 515-520.
244. Nauck MA, E Bartels, C Orskov, R Ebert, W Creutzfeldt. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76(4): 912-917.
245. Ahren B. Islet G Protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 2009; 8(5): 369-385.
246. Doyle ME, JM Egan. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007; 113(3): 546-593.
247. Zhang Y, R Proenca, M Maffei, M Barone, L Leopold, JM Friedman. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372(6505): 425-432.
248. Rossetti L, D Massillon, N Barzilai, et al. Short term effects of leptin on hepatic gluconeogenesis and in vivo insulin action. J Biol Chem 1997; 272(44): 27758-27763.
249. Montague CT, IS Farooqi, JP Whitehead, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387(6636): 903-908.
250. Fehmann HC, C Peiser, HP Bode, et al. Leptin: a potent inhibitor of insulin secretion. Peptides 1997; 18(8): 1267-1273.
251. Kulkarni RN, ZL Wang, RM Wang, et al. Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice. J Clin Invest 1997; 100(11): 2729-2736.
252. Zhao AZ, KE Bornfeldt, JA Beavo. Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. J Clin Invest 1998; 102(5): 869-873.
253. Chen NG, AG Swick, DR Romsos. Leptin constrains acetylcholine-induced insulin secretion from pancreatic islets of ob/ob mice. J Clin Invest 1997; 100(5): 1174-1179.
254. Emilsson V, YL Liu, MA Cawthorne, NM Morton, M Davenport. Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. Diabetes 1997; 46(2): 313-316.
255. Ishida K, T Murakami, A Mizuno, M Iida, M Kuwajima, K Shima. Leptin suppresses basal insulin secretion from rat pancreatic islets. Regul Pept 1997; 70(2-3): 179-182.
256. Kieffer TJ, RS Heller, CA Leech, GG Holz, JF Habener. Leptin suppression of insulin secretion by the activation of ATP-sensitive K+ channels in pancreatic beta-cells. Diabetes 1997; 46(6): 1087-1093.
257. Ookuma M, K Ookuma, DA York. Effects of leptin on insulin secretion from isolated rat pancreatic islets. Diabetes 1998; 47(2): 219-223.
258. Poitout V, C Rouault, M Guerre-Millo, I Briaud, G Reach. Inhibition of insulin secretion by leptin in normal rodent islets of Langerhans. Endocrinology 1998; 139(3): 822-826.
259. Seufert J, TJ Kieffer, JF Habener. Leptin inhibits insulin gene transcription and reverses hyperinsulinemia in leptin-deficient ob/ob mice. Proc Natl Acad Sci U S A 1999; 96(2): 674-679.
260. Fehmann HC, P Berghofer, D Brandhorst, et al. Leptin inhibition of insulin secretion from isolated human islets. Acta Diabetol 1997; 34(4): 249-252.
261. Lupi R, P Marchetti, M Maffei, et al. Effects of acute or prolonged exposure to human leptin on isolated human islet function. Biochem Biophys Res Commun 1999; 256(3): 637-641.
262. Fehmann HC, HP Bode, T Ebert, A Karl, B Goke. Interaction of GLP-I and leptin at rat pancreatic B-cells: effects on insulin secretion and signal transduction. Horm Metab Res 1997; 29(11): 572-576.
263. Ahren B, PJ Havel. Leptin inhibits insulin secretion induced by cellular cAMP in a pancreatic B cell line (INS-1 cells). Am J Physiol 1999; 277(4 Pt 2): R959-R966.
264. Sonksen PH. Insulin, growth hormone and sport. J Endocrinol 2001; 170(1): 13-25.
265. Guler HP, C Schmid, J Zapf, ER Froesch. Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci U S A 1989; 6(8): 2868-2872.
266. Van Schravendijk CF, L Heylen, JL Van den Brande, DG Pipeleers. Direct effect of insulin and insulin-like growth factor-I on the secretory activity of rat pancreatic beta cells. Diabetologia 1990; 33(11): 649-653.
267. Zhang F, K Sjoholm, Q Zhang. Attenuation of insulin secretion by insulin-like growth factor binding protein-1 in pancreatic beta-cells. Biochem Biophys Res Commun 2007; 362(1): 152-157.
268. Cnop M, N Welsh, JC Jonas, A Jorns, S Lenzen, DL Eizirik. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 2005; 54 Suppl 2: S97-107.
269. Sparre T, MR Larsen, PE Heding, AE Karlsen, ON Jensen, F Pociot. Unraveling the pathogenesis of type 1 diabetes with proteomics: present and future directions. Mol Cell Proteomics 2005; 4(4): 441-457.
270. von Herrath M, S Sanda, K Herold. Type 1 diabetes as a relapsingremitting disease? Nat Rev Immunol 2007; 7(12): 988-994.
271. Tisch R, B Wang. Dysrulation of T cell peripheral tolerance in type 1 diabetes. Adv Immunol 2008; 100: 125-149.
272. Tsai S, A Shameli, P Santamaria. CD8+ T cells in type 1 diabetes. Adv Immunol 2008; 100: 79-124.
273. Mandrup-Poulsen T, S Helqvist, J Molvig, LD Wogensen, J Nerup. Cytokines as immune effector molecules in autoimmune endocrine diseases with special reference to insulin-dependent diabetes mellitus. Autoimmunity 1989; 4(3): 191-218; discussion 219-234.
274. Pankewycz OG, JX Guan, JF Benedict. Cytokines as mediators of autoimmune diabetes and diabetic complications. Endocr Rev 1995; 16(2): 164-176.
275. Rabinovitch A, WL Suarez-Pinzon. Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 1998; 55(8): 1139-1149.
276. Cardozo AK, P Proost, C Gysemans, MC Chen, C Mathieu, DL Eizirik. IL-1beta and IFN-gamma induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice. Diabetologia 2003; 46(2): 255-266.
277. Li L, W El-Kholy, CJ Rhodes, PL Brubaker. Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia 2005; 48(7): 1339-1349.
278. Thomas HE, R Darwiche, JA Corbett, TW Kay. Interleukin-1 plus gamma-interferon-induced pancreatic beta-cell dysfunction is mediated by beta-cell nitric oxide production. Diabetes 2002; 51(2): 311-316.
279. Kwon G, JA Corbett, CP Rodi, P Sullivan, ML McDaniel. Interleukin-1 beta-induced nitric oxide synthase expression by rat pancreatic beta-cells: evidence for the involvement of nuclear factor kappa B in the signaling mechanism. Endocrinology 1995; 136(11): 4790-4795.
280. Takamura T, I Kato, N Kimura, et al. Transgenic mice overexpressing type 2 nitric-oxide synthase in pancreatic beta cells develop insulin-dependent diabetes without insulitis. J Biol Chem 1998; 273(5): 2493-2496.
281. Lindsay RM, W Smith, SP Rossiter, MA McIntyre, BC Williams, JD Baird. Nomega-nitro-L-arginine methyl ester reduces the incidence of IDDM in BB/E rats. Diabetes 1995; 44(3): 365-368.
282. Heitmeier MR, AL Scarim, JA Corbett. Interferon-gamma increases the sensitivity of islets of Langerhans for inducible nitricoxide synthase expression induced by interleukin 1. J Biol Chem 1997; 272(21): 13697-13704.
283. Flodstrom M, B Tyrberg, DL Eizirik, S Sandler. Reduced sensitivity of inducible nitric oxide synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes. Diabetes 1999; 48(4): 706-713.
284. Stoffers DA. The development of beta-cell mass: recent progress and potential role of GLP-1. Horm Metab Res 2004; 36(11-12): 811-821.
285. Tourrel C, D Bailbe, M Lacorne, MJ Meile, M Kergoat, B Portha. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 2002; 51(5): 1443-1452.
286. Sakuraba H, H Mizukami, N Yagihashi, R Wada, C Hanyu, S Yagihashi. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 2002; 45(1): 85-96.
287. Marchetti P, S Del Guerra, L Marselli, et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab 2004; 89(11): 5535-5541.
288. Sreenan S, AJ Pick, M Levisetti, AC Baldwin, W Pugh, KS Polonsky. Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes 1999; 48(5): 989-996.
289. Suarez-Pinzon WL, Y Yan, R Power, SJ Brand, A Rabinovitch. Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice. Diabetes 2005; 54(9): 2596-2601.
290. Ogawa N, JF List, JF Habener, T Maki. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 2004; 53(7): 1700-1705.
291. Suarez-Pinzon WL, RF Power, Y Yan, et al. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 2008; 57(12): 3281-3288.
292. Eizirik DL, T Mandrup-Poulsen. A choice of death--the signaltransduction of immune-mediated beta-cell apoptosis. Diabetologia 2001; 44(12): 2115-2133.
293. Hostens K, D Pavlovic, Y Zambre, Z Ling, C Van Schravendijk, DL Eizirik, DG Pipeleers. Exposure of human islets to cytokines can result in disproportionately elevated proinsulin release. J Clin Invest 1999; 104(1): 67-72.
294. Eizirik DL, B Kutlu, J Rasschaert, M Darville, AK Cardozo. Use of microarray analysis to unveil transcription factor and gene networks contributing to Beta cell dysfunction and apoptosis. Ann N Y Acad Sci 2003; 1005: 55-74.
295. Norlin S, U Ahlgren, H Edlund. Nuclear factor-{kappa}B activity in {beta}-cells is required for glucose-stimulated insulin secretion. Diabetes 2005; 54(1): 125-132.
296. Darville MI, DL Eizirik. Regulation by cytokines of the inducible nitric oxide synthase promoter in insulin-producing cells. Diabetologia 1998; 41(9): 1101-1108.
297. Andersson AK, A Borjesson, J Sandgren, S Sandler. Cytokines affect PDX-1 expression, insulin and proinsulin secretion from iNOS deficient murine islets. Mol Cell Endocrinol 2005; 240(1-2): 50-57.
298. Cardozo AK, M Kruhoffer, R Leeman, T Orntoft, DL Eizirik. Identification of novel cytokine-induced genes in pancreatic betacells by high-density oligonucleotide arrays. Diabetes 2001; 50(5): 909-920.
299. Chen MC, P Proost, C Gysemans, C Mathieu, DL Eizirik. Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and in interleukin-1 betaexposed human and rat islet cells. Diabetologia 2001; 44(3): 325-332.
300. Kutlu B, MI Darville, AK Cardozo, DL Eizirik. Molecular regulation of monocyte chemoattractant protein-1 expression in pancreatic beta-cells. Diabetes 2003; 52(2): 348-355.
301. Cardozo AK, H Heimberg, Y Heremans, et al. A comprehensive analysis of cytokine-induced and nuclear factor-kappa B-dependent genes in primary rat pancreatic beta-cells. J Biol Chem 2001; 276(52): 48879-48886.
302. Eizirik DL, AK Cardozo, M Cnop. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 2008; 29(1): 42-61.
303. Oyadomari S, K Takeda, M Takiguchi, et al. Nitric oxide-induced apoptosis in pancreatic beta cells is mediated by the endoplasmic reticulum stress pathway. Proc Natl Acad Sci U S A 2001; 98(19): 10845-10850.
304. Oyadomari S, E Araki, M Mori. Endoplasmic reticulum stressmediated apoptosis in pancreatic beta-cells. Apoptosis 2002; 7(4): 335-345.
305. Ammendrup A, A Maillard, K Nielsen, et al. The c-Jun aminoterminal kinase pathway is preferentially activated by interleukin-1 and controls apoptosis in differentiating pancreatic beta-cells. Diabetes 2000; 49(9): 1468-1476.
306. Negri S, A Oberson, M Steinmann, et al. cDNA cloning and mapping of a novel islet-brain/JNK-interacting protein. Genomics 2000; 64(3): 324-330.
307. Ferdaoussi M, S Abdelli, JY Yang, et al. Exendin-4 protects betacells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway. Diabetes 2008; 57(5): 1205-1215.
308. Bonny C, A Oberson, S Negri, C Sauser, DF Schorderet. Cellpermeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 2001; 50(1): 77-82.
309. Donath MY, PA Halban. Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia 2004; 47(3): 581-589.
310. Weir GC, DR Laybutt, H Kaneto, S Bonner-Weir, A Sharma. Betacell adaptation and decompensation during the progression of diabetes. Diabetes 2001; 50 Suppl 1: S154-159.
311. Zhou YP, K Marlen, JF Palma, A Schweitzer, L Reilly, FM Gregoire, GG Xu, JE Blume, JD Johnson. Overexpression of repressive cAMP response element modulators in high glucose and fatty acid-treated rat islets. A common mechanism for glucose toxicity and lipotoxicity? J Biol Chem 2003; 278(51): 51316-51323.
312. Robertson RP, J Harmon, PO Tran, Y Tanaka, H Takahashi. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003; 52(3): 581-587.
313. Elouil H, AK Cardozo, DL Eizirik, JC Henquin, JC Jonas. High glucose and hydrogen peroxide increase c-Myc and haemeoxygenase 1 mRNA levels in rat pancreatic islets without activating NFkappaB. Diabetologia 2005; 48(3): 496-505.
314. Gurgul E, S Lortz, M Tiedge, A Jorns, S Lenzen. Mitochondrial catalase overexpression protects insulin-producing cells against toxicity of reactive oxygen species and proinflammatory cytokines. Diabetes 2004; 53(9): 2271-2280.
315. Fridlyand LE, LH Philipson. Does the glucose-dependent insulin secretion mechanism itself cause oxidative stress in pancreatic beta-cells? Diabetes 2004; 53(8): 1942-1948.
316. Grill V, A Bjorklund. Overstimulation and beta-cell function. Diabetes 2001; 50 Suppl 1: S122-S124.
317. Maedler K, J Oberholzer, P Bucher, GA Spinas, MY Donath. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes 2003; 52(3): 726-733.
318. Maedler K, GA Spinas, D Dyntar, W Moritz, N Kaiser, MY Donath. Distinct effects of saturated and monounsaturated fatty acids on beta-cell turnover and function. Diabetes 2001; 50(1): 69-76.
319. Kharroubi I, L Ladriere, AK Cardozo, Z Dogusan, M Cnop, DL Eizirik. Free fatty acids and cytokines induce pancreatic beta-cell apoptosis by different mechanisms: role of nuclear factor-kappaB and endoplasmic reticulum stress. Endocrinology 2004; 145(11): 5087-5096.
320. Cnop M, JC Hannaert, A Hoorens, DL Eizirik, DG Pipeleers. Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. Diabetes 2001; 50(8): 1771-1777.
321. Rys-Sikora KE, DL Gill. Fatty acid-mediated calcium sequestration within intracellular calcium pools. J Biol Chem 1998; 273(49): 32627-32635.
322. Bonner-Weir S. Beta-cell turnover: its assessment and implications. Diabetes 2001; 50 Suppl 1: S20-S24.
323. Pick A, J Clark, C Kubstrup, M Levisetti, W Pugh, S Bonner-Weir, KS Polonsky. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 1998; 47(3): 358-364.
324. Kloppel G, M Lohr, K Habich, M Oberholzer, PU Heitz. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 1985; 4(2): 110-125.
325. Buettner R, CB Newgard, CJ Rhodes, RM O'Doherty. Correction of diet-induced hyperglycemia, hyperinsulinemia, and skeletal muscle insulin resistance by moderate hyperleptinemia. Am J Physiol Endocrinol Metab 2000; 278(3): E563-E569.
326. Sherry NA, JA Kushner, M Glandt, T Kitamura, AM Brillantes, KC Herold. Effects of autoimmunity and immune therapy on betacell turnover in type 1 diabetes. Diabetes 2006; 55(12): 3238-3245.
327. Thorel FV, Nepote, I, Avril, K et al. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature 2010; 464(7292): 1149-1154.
328. Bonner-Weir S. Islet growth and development in the adult. J Mol Endocrinol 2000; 24(3): 297-302.
329. Pende M, SC Kozma, M Jaquet, et al. Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature 2000; 408(6815): 994-997.
330. Rhodes CJ, MF White. Molecular insights into insulin action and secretion. Eur J Clin Invest 2002; 32 Suppl 3: 3-13.
331. Hugl SR, MF White, CJ Rhodes. Insulin-like growth factor I (IGFI)- stimulated pancreatic beta-cell growth is glucose-dependent. Synergistic activation of insulin receptor substrate-mediated signal transduction pathways by glucose and IGF-I in INS-1 cells. J Biol Chem 1998; 273(28): 17771-17779.
332. Cousin SP, SR Hugl, MG Myers, Jr., MF White, A Reifel-Miller, CJ Rhodes. Stimulation of pancreatic beta-cell proliferation by growth hormone is glucose-dependent: signal transduction via janus kinase 2 (JAK2)/signal transducer and activator of transcription 5 (STAT5) with no crosstalk to insulin receptor substrate-mediated mitogenic signalling. Biochem J 1999; 344 Pt 3: 649-658.
333. Donath MY, DJ Gross, E Cerasi, N Kaiser. Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes 1999; 48(4): 738-744.
334. Galsgaard ED, F Gouilleux, B Groner, P Serup, JH Nielsen, N Billestrup. Identification of a growth hormone-responsive STAT5- binding element in the rat insulin 1 gene. Mol Endocrinol 1996; 10(6): 652-660.
335. Brelje TC, LE Stout, NV Bhagroo, RL Sorenson. Distinctive roles for prolactin and growth hormone in the activation of signal transducer and activator of transcription 5 in pancreatic islets of langerhans. Endocrinology 2004; 145(9): 4162-4175.
336. Friedrichsen BN, HE Richter, JA Hansen, et al. Signal transducer and activator of transcription 5 activation is sufficient to drive transcriptional induction of cyclin D2 gene and proliferation of rat pancreatic beta-cells. Mol Endocrinol 2003; 17(5): 945-958.
337. Rulifson IC, SK Karnik, PW Heiser, et al. Wnt signaling regulates pancreatic beta cell proliferation. Proc Natl Acad Sci U S A 2007; 104(15): 6247-6252.
338. Nielsen JH, ED Galsgaard, A Moldrup, BN Friedrichsen, N Billestrup, JA Hansen, YC Lee, C Carlsson. Regulation of beta-cell mass by hormones and growth factors. Diabetes 2001; 50 Suppl 1: S25-S29.
339. Bruning JC, J Winnay, S Bonner-Weir, SI Taylor, D Accili, CR Kahn. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell 1997; 88(4): 561-572.
340. Tuttle RL, NS Gill, W Pugh,et al Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nat Med 2001; 7(10): 1133-1137.
341. Frystyk J, C Skjaerbaek, E Vestbo, S Fisker, H Orskov. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev 1999; 15(5): 314-22.
342. Dickson LM, MK Lingohr, J McCuaig, SR Hugl, L Snow, BB Kahn, MG Myers, Jr., CJ Rhodes. Differential activation of protein kinase B and p70(S6)K by glucose and insulin-like growth factor 1 in pancreatic beta-cells (INS-1). J Biol Chem 2001; 276(24): 21110-21120.
343. Chan TO, SE Rittenhouse, PN Tsichlis. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 1999; 68: 965-1014.
344. Bottazzo GF, A Florin-Christensen, D Doniach. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974; 2(7892): 1279-1283.
345. Palmer JP, CM Asplin, P Clemons, K Lyen, et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983; 222(4630): 1337-1339.
346. Kuglin B, FA Gries, H Kolb. Evidence of IgG autoantibodies against human proinsulin in patients with IDDM before insulin treatment. Diabetes 1988; 37(1): 130-132.
347. Baekkeskov S, HJ Aanstoot, S Christgau, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABAsynthesizing enzyme glutamic acid decarboxylase. Nature 1990; 347(6289): 151-156.
348. Christie MR, RY Tun, SS Lo, et al. Antibodies to GAD and tryptic fragments of islet 64K antigen as distinct markers for development of IDDM. Studies with identical twins. Diabetes 1992; 41(7): 782-787.
349. Foulis AK, MA Farquharson, R Hardman. Aberrant expression of class II major histocompatibility complex molecules by B cells and hyperexpression of class I major histocompatibility complex molecules by insulin containing islets in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987; 30(5): 333-343.
350. Root EJ, GF Combs, Jr. Disruption of endoplasmic reticulum is the primary ultrastructural lesion of the pancreas in the seleniumdeficient chick. Proc Soc Exp Biol Med 1988; 187(4): 513-521.
351. Feutren G, L Papoz, R Assan, et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986; 2(8499): 119-124.
352. Ziegler AG, S Schmid, D Huber, M Hummel, E Bonifacio. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA 2003; 290(13): 1721-1728.
353. Littorin B, P Blom, A Scholin, et al. Lower levels of plasma 25- hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes Incidence Study in Sweden (DISS). Diabetologia 2006; 49(12): 2847-2852.
354. Frisk G, T Hansson, I Dahlbom, T Tuvemo. A unifying hypothesis on the development of type 1 diabetes and celiac disease: gluten consumption may be a shared causative factor. Med Hypotheses 2008; 70(6): 1207-1209.
355. Pugliese A. Genetics of type 1 diabetes. Endocrinol Metab Clin North Am 2004; 33(1): 1-16, 7.
356. Pino SC, AJ Kruger, R Bortell. The role of innate immune pathways in type 1 diabetes pathogenesis. Curr Opin Endocrinol Diabetes Obes 2010.
357. Bingley PJ, MR Christie, E Bonifacio, et al. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibodypositive relatives. Diabetes 1994; 43(11): 1304-1310.
358. Notkins AL, A Lernmark. Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest 2001; 108(9): 1247-1252.
359. Wallet MA, R Tisch. Type 1 diabetes, inflammation and dendritic cells. Drug Discovery Today 2006; 3(3): 373-379.
360. Knip M, H Siljander. Autoimmune mechanisms in type 1 diabetes. Autoimmun Rev 2008; 7(7): 550-557.
361. Roep BO. The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure. Diabetologia 2003; 46(3): 305-321.
362. Guberski DL, L Butler, W Kastern, AA Like. Genetic studies in inbred BB/Wor rats. Analysis of progeny produced by crossing lymphopenic diabetes-prone rats with nonlymphopenic diabetic rats. Diabetes 1989; 38(7): 887-893.
363. MacMurray AJ, DH Moralejo, AE Kwitek, et al. Lymphopenia in the BB rat model of type 1 diabetes is due to a mutation in a novel immune-associated nucleotide (Ian)-related gene. Genome Res 2002; 12(7): 1029-1039.
364. Schulze-Koops H. Lymphopenia and autoimmune diseases. Arthritis Res Ther 2004; 6(4): 178-180.
365. King C, A Ilic, K Koelsch, N Sarvetnick. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004; 117(2): 265-277.
366. Cho BK, VP Rao, Q Ge, HN Eisen, J Chen. Homeostasisstimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med 2000; 192(4): 549-556.
367. Isaacs JD, S Greer, S Sharma, et al. Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapyinduced lymphopenia. Arthritis Rheum 2001; 44(9): 1998-2008.
368. Thivolet C, A Bendelac, P Bedossa, JF Bach, C Carnaud. CD8+ T cell homing to the pancreas in the nonobese diabetic mouse is CD4+ T cell-dependent. J Immunol 1991; 146(1): 85-88.
369. Romagnani S. Biology of human TH1 and TH2 cells. J Clin Immunol 1995; 15(3): 121-129.
370. Mosmann TR, RL Coffman. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145-173.
371. Almawi WY, H Tamim, ST Azar. Clinical review 103: T helper type 1 and 2 cytokines mediate the onset and progression of type I (insulin-dependent) diabetes. J Clin Endocrinol Metab 1999; 84(5): 1497-1502.
372. Bucy RP, L Karr, GQ Huang, et al. Single cell analysis of cytokine gene coexpression during CD4+ T-cell phenotype development. Proc Natl Acad Sci U S A 1995; 92(16): 7565-7569.
373. Seder RA, R Ahmed. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 2003; 4(9): 835-842.
374. Katz JD, C Benoist, D Mathis. Thelper cell subsets in insulindependent diabetes. Science 1995; 268(5214): 1185-1188.
375. Liblau RS, SM Singer, HO McDevitt. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16(1): 34-38.
376. Pilstrom B, L Bjork, J Bohme. Monokine-producing cells predominate in the recruitment phase of NOD insulitis while cells producing Th1-type cytokines characterize the effector phase. J Autoimmun 1997; 10(2): 147-155.
377. Faust A, H Rothe, U Schade, E Lampeter, H Kolb. Primary nonfunction of islet grafts in autoimmune diabetic nonobese diabetic mice is prevented by treatment with interleukin-4 and interleukin-10. Transplantation 1996; 62(5): 648-652.
378. Held W, HR MacDonald, IL Weissman, MW Hess, C Mueller. Genes encoding tumor necrosis factor alpha and granzyme A are expressed during development of autoimmune diabetes. Proc Natl Acad Sci U S A 1990; 87(6): 2239-2243.
379. Berman MA, CI Sandborg, Z Wang, et al. Decreased IL-4 production in new onset type I insulin-dependent diabetes mellitus. J Immunol 1996; 157(10): 4690-4696.
380. Lee MS, L Wogensen, J Shizuru, MB Oldstone, N Sarvetnick. Pancreatic islet production of murine interleukin-10 does not inhibit immune-mediated tissue destruction. J Clin Invest 1994; 93(3): 1332-1338.
381. Wick M, P Dubey, H Koeppen, et al. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med 1997; 186(2): 229-238.
382. Moritani M, K Yoshimoto, F Tashiro, et al. Transgenic expression of IL-10 in pancreatic islet A cells accelerates autoimmune insulitis and diabetes in non-obese diabetic mice. Int Immunol 1994; 6(12): 1927-1936.
383. Szabo SJ, ST Kim, GL Costa, X Zhang, CG Fathman, LH Glimcher. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100(6): 655-669.
384. Neurath MF, B Weigmann, S Finotto, et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med 2002; 195(9): 1129-1143.
385. Chakir H, H Wang, DE Lefebvre, J Webb, FW Scott. T-bet/GATA- 3 ratio as a measure of the Th1/Th2 cytokine profile in mixed cell populations: predominant role of GATA-3. J Immunol Methods 2003; 278(1-2): 157-169.
386. Piccirillo CA, EM Shevach. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001; 167(3): 1137-1140.
387. Randolph DA, CG Fathman. Cd4+Cd25+ regulatory T cells and their therapeutic potential. Annu Rev Med 2006; 57: 381-402.
388. Chen Z, AE Herman, M Matos, D Mathis, C Benoist. Where CD4+CD25+ T reg cells impinge on autoimmune diabetes. J Exp Med 2005; 202(10): 1387-1397.
389. Brusko T, M Atkinson. Treg in type 1 diabetes. Cell Biochem Biophys 2007; 48(2-3): 165-175.
390. Filippi C, D Bresson, M von Herrath. Antigen-specific induction of regulatory T cells for type 1 diabetes therapy. Int Rev Immunol 2005; 24(5-6): 341-360.
391. Gagnerault MC, JJ Luan, C Lotton, F Lepault. Pancreatic lymph nodes are required for priming of beta cell reactive T cells in NOD mice. J Exp Med 2002; 196(3): 369-377.
392. McKenzie MD, NL Dudek, L Mariana, et al. Perforin and Fas induced by IFNgamma and TNFalpha mediate beta cell death by OT-I CTL. Int Immunol 2006; 18(6): 837-846.
393. Shi L, RP Kraut, R Aebersold, AH Greenberg. A natural killer cell granule protein that induces DNA fragmentation and apoptosis. J Exp Med 1992; 175(2): 553-566.
394. Sullivan BM, A Juedes, SJ Szabo, M von Herrath, LH Glimcher. Antigen-driven effector CD8 T cell function regulated by T-bet. Proc Natl Acad Sci U S A 2003; 100(26): 15818-15823.
395. Chabaud M, P Garnero, JM Dayer, PA Guerne, F Fossiez, P Miossec. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 2000; 12(7): 1092-109.
396. Suzuki Y, Y Kuroda, A Morita, et al. Fibrin glue sealing for the prevention of pancreatic fistulas following distal pancreatectomy. Arch Surg 1995; 130(9): 952-955.
397. Graber JJ, SR Allie, KM Mullen, MV Jones, T Wang, C Krishnan, AI Kaplin, A Nath, DA Kerr, PA Calabresi. Interleukin-17 in transverse myelitis and multiple sclerosis. J Neuroimmunol 2008; 196(1-2): 124-132.
398. Annunziato F, L Cosmi, V Santarlasci, et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007; 204(8): 1849-1861.
399. Lee YK, H Turner, CL Maynard, et al. Late developmental plasticity in the T helper 17 lineage. Immunity 2009; 30(1): 92-107.
400. Vukkadapu SS, JM Belli, K Ishii, et al. Dynamic interaction between T cell-mediated beta-cell damage and beta-cell repair in the run up to autoimmune diabetes of the NOD mouse. Physiol Genomics 2005; 21(2): 201-211.
401. Jain R, DM Tartar, RK Gregg, RD Divekar, et al. Innocuous IFNgamma induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production. J Exp Med 2008; 205(1): 207-218.
402. Cozar-Castellano I, N Fiaschi-Taesch, TA Bigatel, et al. Molecular control of cell cycle progression in the pancreatic beta-cell. Endocr Rev 2006; 27(4): 356-370.
403. Kahn SE, RL Hull, KM Utzschneider. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444(7121): 840-846.
404. Butler AE, J Janson, S Bonner-Weir, R Ritzel, RA Rizza, PC Butler. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52(1): 102-110.
405. Pietropaolo M, D Le Roith. Pathogenesis of diabetes: our current understanding. Clin Cornerstone 2001; 4(2): 1-16.
406. Prentki M, CJ Nolan. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006; 116(7): 1802-1812.
407. Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science 2005; 307(5708): 380-384.
408. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46(1): 3-10.
409. Polonsky KS. Dynamics of insulin secretion in obesity and diabetes. Int J Obes Relat Metab Disord 2000; 24 Suppl 2: S29-S31.
410. Flier SN, RN Kulkarni, CR Kahn. Evidence for a circulating islet cell growth factor in insulin-resistant states. Proc Natl Acad Sci U S A 2001; 98(13): 7475-7480.
411. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3(3): 153-165.
412. Van Citters GW, M Kabir, SP Kim, SD Mittelman, MK Dea, PL Brubaker, RN Bergman. Elevated glucagon-like peptide-1-(7-36)-amide, but not glucose, associated with hyperinsulinemic compensation for fat feeding. J Clin Endocrinol Metab 2002; 87(11): 5191-5198.
413. Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1998; 40 Suppl: S21-S25.
414. Jaikaran ET, A Clark. Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim Biophys Acta 2001; 1537(3): 179-203.
415. Poitout V, J Amyot, M Semache, B Zarrouki, D Hagman, G Fontes. Glucolipotoxicity of the pancreatic beta cell. Biochim Biophys Acta 2010; 1801(3): 289-298.
416. Poitout V. Glucolipotoxicity of the pancreatic beta-cell: myth or reality? Biochem Soc Trans 2008; 36(Pt 5): 901-904.
417. Poitout V, RP Robertson. Glucolipotoxicity: fuel excess and betacell dysfunction. Endocr Rev 2008; 29(3): 351-366.
418. Zhao NQ, YR Yu, HW Tan, G Deng, XX Zhang. [Role of apoptosis and mitochondrial apoptotic pathway in glucolipotoxicity-induced islet beta-cell dysfunction]. Nan Fang Yi Ke Da Xue Xue Bao 2008; 28(11): 2009-2013.
419. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28(2): 187-218.
420. Chang-Chen KJ, R Mullur, E Bernal-Mizrachi. Beta-cell failure as a complication of diabetes. Rev Endocr Metab Disord 2008; 9(4): 329-343.
421. Poitout V, RP Robertson. Minireview: Secondary beta-cell failure in type 2 diabetes--a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002; 143(2): 339-342.
422. Khaldi MZ, Y Guiot, P Gilon, JC Henquin, JC Jonas. Increased glucose sensitivity of both triggering and amplifying pathways of insulin secretion in rat islets cultured for 1 wk in high glucose. Am J Physiol Endocrinol Metab 2004; 287(2): E207-E217.
423. Maedler K, P Sergeev, F Ris, J Oberholzer, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110(6): 851-860.
424. Ohara-Imaizumi M, AK Cardozo, T Kikuta, DL Eizirik, S Nagamatsu. The cytokine interleukin-1 beta reduces the docking and fusion of insulin granules in pancreatic beta-cells, preferentially decreasing the first phase of exocytosis. J Biol Chem 2004; 279(40): 41271-41274.
425. Kajimoto Y, T Matsuoka, H Kaneto, et al. Induction of glycation suppresses glucokinase gene expression in HIT-T15 cells. Diabetologia 1999; 42(12): 1417-1424.
426. Tajiri Y, C Moller, V Grill. Long-term effects of aminoguanidine on insulin release and biosynthesis: evidence that the formation of advanced glycosylation end products inhibits B cell function. Endocrinology 1997; 138(1): 273-280.
427. Tanaka Y, CE Gleason, PO Tran, JS Harmon, RP Robertson. Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc Natl Acad Sci U S A 1999; 96(19): 10857-10862.
428. Kaneto H, Y Kajimoto, J Miyagawa, M Hori, et al. Beneficial effects of antioxidants in diabetes - Possible protection of pancreatic beta-cells against glucose toxicity. Diabetes 1999; 48(12): 2398-2406.
429. Ihara Y, S Toyokuni, K Uchida, et al. Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. Diabetes 1999; 48(4): 927-932.
430. Matsuoka T, Y Kajimoto, H Watada, H Kaneto, M Kishimoto, Y Umayahara, Y Fujitani, T Kamada, R Kawamori, Y Yamasaki. Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells. J Clin Invest 1997; 99(1): 144-150.
431. Kaneto H, J Fujii, T Myint, N Miyazawa, et al. Reducing sugars trigger oxidative modification and apoptosis in pancreatic betacells by provoking oxidative stress through the glycation reaction. Biochem J 1996; 320 (Pt 3): 855-863.
432. Grankvist K, SL Marklund, IB Taljedal. CuZn-superoxide dismutase, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse. Biochem J 1981; 199(2): 393-398.
433. Malaisse WJ, F Malaisse-Lagae, A Sener, DG Pipeleers. Determinants of the selective toxicity of alloxan to the pancreatic B cell. Proc Natl Acad Sci U S A 1982; 79(3): 927-930.
434. Grankvist K, S Marklund, IB Taljedal. Superoxide dismutase is a prophylactic against alloxan diabetes. Nature 1981; 294(5837): 158-160.
435. Tanaka Y, PO Tran, J Harmon, RP Robertson. A role for glutathione peroxidase in protecting pancreatic beta cells against oxidative stress in a model of glucose toxicity. Proc Natl Acad Sci U S A 2002; 99(19): 12363-12368.
436. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40(4): 405-412.
437. Wolff SP, RT Dean. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J 1987; 245(1): 243-250.
438. Hunt JV, RT Dean, SP Wolff. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochem J 1988; 256(1): 205-212.
439. Kaneto H, G Xu, KH Song, et al. Activation of the hexosamine pathway leads to deterioration of pancreatic beta-cell function through the induction of oxidative stress. J Biol Chem 2001; 276(33): 31099-31104.
440. Kaneto H, G Xu, N Fujii, S Kim, S Bonner-Weir, GC Weir. Involvement of c-Jun N-terminal kinase in oxidative stressmediated suppression of insulin gene expression. J Biol Chem 2002; 277(33): 30010-30018.
441. Withers DJ, JS Gutierrez, H Towery, et al. MF White. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998; 391(6670): 900-904.
442. Kubota N, Y Terauchi, K Tobe, et al. Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J Clin Invest 2004; 114(7): 917-927.
443. Bruning JC, J Winnay, B Cheatham, CR Kahn. Differential signaling by insulin receptor substrate 1 (IRS-1) and IRS-2 in IRS- 1-deficient cells. Mol Cell Biol 1997; 17(3): 1513-1521.
444. Martinez SC, K Tanabe, C Cras-Meneur, NA Abumrad, E Bernal- Mizrachi, MA Permutt. Inhibition of Foxol protects pancreatic islet beta-cells against fatty acid and endoplasmic reticulum stressinduced apoptosis. Diabetes 2008; 57(4): 846-859.
445. Wullschleger S, R Loewith, MN Hall. TOR signaling in growth and metabolism. Cell 2006; 124(3): 471-484.
446. Mori H, K Inoki, D Opland, et al. Critical roles for the TSC-mTOR pathway in {beta}-cell function. Am J Physiol Endocrinol Metab 2009.
447. Loewith R, E Jacinto, S Wullschleger, A Lorberg, JL Crespo, D Bonenfant, W Oppliger, P Jenoe, MN Hall. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002; 10(3): 457-468.
448. Briaud IM, MK Lingohr, LM Dickson, JF McCuaig, JC Lawrence, CJ Rhodes. IRS-2 proteasomal degradation mediated by a mTORinduced negative feedback downregulates PKB-mediated signaling pathway in beta-cells. Diabetologia 2004; 47: A26-A26.
449. Jhala US, G Canettieri, RA Screaton, RN Kulkarni, S Krajewski, J Reed, J Walker, X Lin, M White, M Montminy. CAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev 2003; 17(13): 1575-1580.
450. Olson LK, JB Redmon, HC Towle, RP Robertson. Chronic Exposure of Hit Cells to High Glucose-Concentrations Paradoxically Decreases Insulin Gene-Transcription and Alters Binding of Insulin Gene Regulatory Protein. J Clin Invest 1993; 92(1): 514-519.
451. Park KG, KM Lee, HY Seo, et al. Glucotoxicity in the INS-1 rat insulinoma cell line is mediated by the orphan nuclear receptor small heterodimer partner. Diabetes 2007; 56(2): 431-437.
452. Olson LK, A Sharma, M Peshavaria, CVE Wright, HC Towle, RP Robertson, R Stein. Reduction of Insulin Gene-Transcription in Hit-T15 Beta-Cells Chronically Exposed to a Supraphysiological Glucose-Concentration Is Associated with Loss of Stf-1 Transcription Factor Expression (Vol 92, Pg 9127, 1995). Proc Natl Acad Sci U S A 1995; 92(24): 11322-11322.
453. Sharma A, LK Olson, RP Robertson, R Stein. The Reduction of Insulin Gene-Transcription in Hit-T15 Beta-Cells Chronically Exposed to High Glucose-Concentration Is Associated with the Loss of Ripe3b1 and Stf-1 Transcription Factor Expression. Mol Endocrinol 1995; 9(9): 1127-1134.
454. Poitout V, LK Olson, RP Robertson. Chronic exposure of beta TC- 6 cells to supraphysiologic concentrations of glucose decreases binding of the RIPE3b1 insulin gene transcription activator. J Clin Invest 1996; 97(4): 1041-1046.
455. Lu M, J Seufert, JF Habener. Pancreatic beta-cell-specific repression of insulin gene transcription by CCAAT enhancerbinding protein beta - Inhibitory interactions with basic helix-loophelix transcription factor E47. J Biol Chem 1997; 272(45): 28349-28359.
456. Seufert J, GC Weir, JF Habener. Differential expression of the insulin gene transcriptional repressor CCAAT/enhancer-binding protein beta and transactivator islet duodenum homeobox-1 in rat pancreatic beta cells during the development of diabetes mellitus. J Clin Invest 1998; 101(11): 2528-2539.
457. Kharroubi I, L Ladriere, AK Cardozo, M Cnop, DL Eizirik. Free fatty acids and cytokines induce pancreatic beta cell apoptosis by different mechanisms: role of NF-kappa B and endoplasmic reticulum stress. Diabetologia 2004; 47: A176-A176.
458. Eizirik DL. Interleukin-1 Induced Impairment in Pancreatic-Islet Oxidative-Metabolism of Glucose Is Potentiated by Tumor Necrosis Factor. Acta Endocrinologica 1988; 119(3): 321-325.
459. Prentki M, BE Corkey. Are the beta-cell signaling molecules malonyl-CoA and cystolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Diabetes 1996; 45(3): 273-283.
460. Roche E, S Farfari, LA Witters, F Assimacopoulos-Jeannet, S Thumelin, T Brun, BE Corkey, AK Saha, M Prentki. Long-term exposure of beta-INS cells to high glucose concentrations increases anaplerosis, lipogenesis, and lipogenic gene expression. Diabetes 1998; 47(7): 1086-1094.
461. Ruderman N, M Prentki. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 2004; 3(4): 340-351.
462. Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 2003; 144(12): 5179-5183.
463. Salt IP, G Johnson, SJ Ashcroft, DG Hardie. AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. Biochem J 1998; 335 (Pt 3): 533-539.
464. Wang X, L Zhou, G Li, et al. Palmitate activates AMP-activated protein kinase and regulates insulin secretion from beta cells. Biochem Biophys Res Commun 2007; 352(2): 463-468.
465. Foufelle F, P Ferre. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J 2002; 366(Pt 2): 377-391.
466. Shimabukuro M, M Higa, YT Zhou, MY Wang, CB Newgard, RH Unger. Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. J Biol Chem 1998; 273(49): 32487-32490.
467. Moore PC, MA Ugas, DK Hagman, SD Parazzoli, V Poitout. Evidence against the involvement of oxidative stress in fatty acid inhibition of insulin secretion. Diabetes 2004; 53(10): 2610-2616.
468. Cnop M, JC Hannaert, AY Grupping, DG Pipeleers. Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology 2002; 143(9): 3449-3453.
469. Sako Y, VE Grill. A 48-Hour Lipid Infusion in the Rat Time- Dependently Inhibits Glucose-Induced Insulin-Secretion and B Cell Oxidation through a Process Likely Coupled to Fatty-Acid Oxidation. Endocrinology 1990; 127(4): 1580-1589.
470. Elks ML. Chronic perifusion of rat islets with palmitate suppresses glucose-stimulated insulin release. Endocrinology 1993; 133(1): 208-214.
471. Zhou YP, V Grill. Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab 1995; 80(5): 1584-1590.
472. Zhou YP, VE Grill. Long-Term Exposure of Rat Pancreatic-Islets to Fatty-Acids Inhibits Glucose-Induced Insulin-Secretion and Biosynthesis through a Glucose Fatty-Acid Cycle. J Clin Invest 1994; 93(2): 870-876.
473. Briaud I, CL Kelpe, LM Johnson, PO Tran, V Poitout. Differential effects of hyperlipidemia on insulin secretion in islets of langerhans from hyperglycemic versus normoglycemic rats. Diabetes 2002; 51(3): 662-668.
474. Chan CB, D De Leo, JW Joseph, et al. Increased uncoupling protein-2 levels in beta-cells are associated with impaired glucosestimulated insulin secretion: mechanism of action. Diabetes 2001; 50(6): 1302-1310.
475. Schmitz-Peiffer C, DR Laybutt, JG Burchfield, E Gurisik, S Narasimhan, CJ Mitchell, DJ Pedersen, U Braun, GJ Cooney, M Leitges, TJ Biden. Inhibition of PKCepsilon improves glucosestimulated insulin secretion and reduces insulin clearance. Cell Metab 2007; 6(4): 320-328.
476. Olofsson CS, S Collins, M Bengtsson, et al. Long-term exposure to glucose and lipids inhibits glucose-induced insulin secretion downstream of granule fusion with plasma membrane. Diabetes 2007; 56(7): 1888-1897.
477. Hoppa MB, S Collins, R Ramracheya, et al. Chronic palmitate exposure inhibits insulin secretion by dissociation of Ca(2+) channels from secretory granules. Cell Metab 2009; 10(6): 455-465.
478. Lowell BB, GI Shulman. Mitochondrial dysfunction and type 2 diabetes. Science 2005; 307(5708): 384-387.
479. Anello M, R Lupi, D Spampinato, et al. Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. Diabetologia 2005; 48(2): 282-289.
480. Zhang CY, G Baffy, P Perret, et al. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell 2001; 105(6): 745-755.
481. Schiff M, S Loublier, A Coulibaly, P Benit, HO de Baulny, P Rustin. Mitochondria and diabetes mellitus: untangling a conflictive relationship? J Inherit Metab Dis 2009; 32(6): 684-698.
482. Maechler P, CB Wollheim. Mitochondrial function in normal and diabetic beta-cells. Nature 2001; 414(6865): 807-812.
483. Krauss S, CY Zhang, L Scorrano, et al. Superoxide-mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction. J Clin Invest 2003; 112(12): 1831-1842.
484. Mulder H, C Ling. Mitochondrial dysfunction in pancreatic betacells in Type 2 diabetes. Mol Cell Endocrinol 2009; 297(1-2): 34-40.
485. Toye AA, JD Lippiat, P Proks, K Shimomura, L Bentley, A Hugill, V Mijat, M Goldsworthy, L Moir, A Haynes, J Quarterman, HC Freeman, FM Ashcroft, RD Cox. A genetic and physiological study of impaired glucose homeostasis control in C57BL/6J mice. Diabetologia 2005; 48(4): 675-686.
486. Freeman H, K Shimomura, E Horner, RD Cox, FM Ashcroft. Nicotinamide nucleotide transhydrogenase: a key role in insulin secretion. Cell Metab 2006; 3(1): 35-45.
487. Trifunovic A, NG Larsson. Mitochondrial dysfunction as a cause of ageing. J Intern Med 2008; 263(2): 167-178.
488. Seo HY, YD Kim, KM Lee, et al. Endoplasmic reticulum stressinduced activation of activating transcription factor 6 decreases insulin gene expression via up-regulation of orphan nuclear receptor small heterodimer partner. Endocrinology 2008; 149(8): 3832-3841.
489. Mori K. Tripartite management of unfolded proteins in the endoplasmic reticulum. Cell 2000; 101(5): 451-454.
490. Haze K, H Yoshida, H Yanagi, T Yura, K Mori. Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress. Mol Biol Cell. 1999; 10(11): 3787-3799.
491. Shen X, K Zhang, RJ Kaufman. The unfolded protein response-a stress signaling pathway of the endoplasmic reticulum. J Chem Neuroanat 2004; 28(1-2): 79-92.
492. Barone MV, A Crozat, A Tabaee, L Philipson, D Ron. Chop (Gadd153) and Its Oncogenic Variant, Tls-Chop, Have Opposing Effects on the Induction of G(1)/S Arrest. Genes & Development 1994; 8(4): 453-464.
493. Korennykh AV, PF Egea, AA Korostelev, J Finer-Moore, C Zhang, KM Shokat, RM Stroud, P Walter. The unfolded protein response signals through high-order assembly of Ire1. Nature 2009; 457(7230): 687-U2.
494. Wheeler E, I Barroso. Genome-wide association studies and type 2 diabetes. Brief Funct Genomics 2011; 10(2): 52-60.
495. Frayling TM. Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet 2007; 8(9): 657-662.
496. Gloyn AL, MN Weedon, KR Owen, et al. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 2003; 52(2): 568-572.
497. Grant SF, G Thorleifsson, I Reynisdottir, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38(3): 320-323.
498. Sladek R, G Rocheleau, J Rung, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007; 445(7130): 881-885.
499. Scott LJ, KL Mohlke, LL Bonnycastle, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007; 316(5829): 1341-1345.
500. Steinthorsdottir V, G Thorleifsson, I Reynisdottir, et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 2007; 39(6): 770-775